To (anti-)TNF or not (anti-)TNF? That is the question in pemphigus

British Journal of Dermatology

Volumn 172, Issue 3, 2015, Pages 564-565

  Sinha, A A ^a  

^a UNIVERSITY AT BUFFALO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AUTOANTIBODY; CELL ADHESION MOLECULE; DESMOGLEIN 1 ANTIBODY; DESMOGLEIN 3 ANTIBODY; INFLIXIMAB; LEUKOCYTE ANTIGEN; PLACEBO; PREDNISONE; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR INHIBITOR; DERMATOLOGICAL AGENT;

ACANTHOLYSIS; ADVERSE OUTCOME; BLISTER; CLINICAL ASSESSMENT; CLINICAL DECISION MAKING; COCHRANE LIBRARY; CYTOKINE PRODUCTION; DISEASE ACTIVITY; DISEASE ASSOCIATION; DRUG SAFETY; EXPERIMENTAL STUDY; FOLLOW UP; HUMAN; IN VITRO STUDY; INFLAMMATION; KERATINOCYTE; LEUKOCYTE; MORTALITY; NOTE; OUTCOME ASSESSMENT; PATHOGENESIS; PEMPHIGUS DISEASE ACTIVITY INDEX; PEMPHIGUS VULGARIS; PRACTICE GUIDELINE; PRIORITY JOURNAL; PSORIASIS; QUALITATIVE ANALYSIS; QUANTITATIVE ANALYSIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); RHEUMATOID ARTHRITIS; SKIN DISEASE ASSESSMENT; T LYMPHOCYTE; TARGET CELL; TH1 CELL; TH17 CELL; TH2 CELL; THERAPY; TREATMENT RESPONSE; UPREGULATION; WOUND HEALING; FEMALE; MALE; PEMPHIGUS;

DERMATOLOGIC AGENTS; FEMALE; HUMANS; INFLIXIMAB; MALE; PEMPHIGUS; PREDNISONE;

EID: 84925238472     PISSN: 00070963     EISSN: 13652133     Source Type: Journal    
DOI: 10.1111/bjd.13664     Document Type: Note

References (11)

1. Langan SM, Smeeth L, Hubbard R, et al,. Bullous pemphigoid and pemphigus vulgaris-incidence and mortality in the UK: population based cohort study. BMJ 2008; 337: a180.
2. Martin LK, Werth V, Villanueva E, et al,. Interventions for pemphigus vulgaris and pemphigus foliaceus. Cochrane Database Syst Rev 2009; 1: CD006263.
3. Martin LK, Werth VP, Villaneuva EV, Murrell DF,. A systematic review of randomized controlled trials for pemphigus vulgaris and pemphigus foliaceus. J Am Acad Dermatol 2011; 64: 903-8.
4. Giordano CN, Sinha AA,. Cytokine networks in pemphigus vulgaris: an integrated viewpoint. Autoimmunity 2012; 45: 427-39.
5. Feliciani C, Toto P, Amerio P, et al,. In vitro and in vivo expression of interleukin-1alpha and tumor necrosis factor-alpha mRNA in pemphigus vulgaris: interleukin-1alpha and tumor necrosis factor-alpha are involved in acantholysis. J Invest Dermatol 2000; 114: 71-7.
6. Berookhim B, Fischer HD, Weinberg JM,. Treatment of recalcitrant pemphigus vulgaris with the tumor necrosis factor alpha antagonist etanercept. Cutis 2004; 74: 245-7.
7. Pardo J, Mercader P, Mahiques L, et al,. Infliximab in the management of severe pemphigus vulgaris. Br J Dermatol 2005; 153: 222-3.
8. Jacobi A, Shuler G, Hertl M,. Rapid control of therapy-refractory pemphigus vulgaris by treatment with the tumour necrosis factor-alpha inhibitor infliximab. Br J Dermatol 2005; 153: 448-9.
9. Lin MH, Hsu CK, Lee JY,. Successful treatment of recalcitrant pemphigus vulgaris and pemphigus vegetans with etanercept and carbon dioxide laser. Arch Dermatol 2005; 141: 680-2.
10. Shetty A, Marcum CB, Glass LF, Carter JD,. Successful treatment of pemphigus vulgaris with etanercept in four patients. J Drugs Dermatol 2009; 8: 940-3.
11. Hall RP, Fairley J, Woodley D, et al,. A multicentre randomized trial of the treatment of patients with pemphigus vulgaris with infliximab and prednisone compared with prednisone alone. Br J Dermatol 2015; 172: 760-68.